"Nothing is undruggable!" was the bold claim at the European Society of Medical Oncology Targeted Anticancer Therapies Virtual Congress 2021 the (ESMO-TAT).
In the public mind, fat and unhealthy are more or less synonymous. But reality is more complicated, as reality often is. Even among individuals with a BMI of 30 or higher, somewhere between 15% and 45% have metabolism typical of much lower-weight individuals.
Scientists, despite their best efforts, have not been able to identify a way to inhibit the oncoprotein Myc. Uropathogenic Escherichia coli, though, has apparently figured it out. In the Feb. 11, 2021, online issue of Nature Biotechnology, researchers reported that an UPEC-produced protease depleted cellular Myc and improved survival in mouse models of bladder and colon cancer.
Keeping you up to date on recent developments in oncology, including: Imaging studies offer clarity on impact of combo therapy in metastatic breast cancer; Antidiarrheal drug fights AML; Peering past gastrointestinal mucosa to find tumors; Nanosac to the rescue for solid tumor therapy.
A team led by researchers at Johns Hopkins University School of Medicine has developed bispecific antibodies that were able to target tumors driven by mutations in the tumor suppressor TP53 and the oncogene RAS, as well as subsets of T cells in T-cell malignancies.
Keeping you up to date on recent developments in diagnostics, including: Atherosclerosis precedes clonal hematopoiesis; AI-driven tool to assess kidney function; Deep learning-powered classification of lung cancer types.
Scientists, despite their best efforts, have not been able to identify a way to inhibit the oncoprotein Myc. Uropathogenic Escherichia coli, though, has apparently figured it out.
